Reduced nSMase activity following BSO treatment was associated with a decrease in the content of the pro-apoptotic ceramide [7,8] in accord with impaired nSMase activity being reproducibly considered a major underlying mechanism for the reduced ceramide levels in HCC tissues [43]. The gene discussed is SMPD2; the disease is hepatocellular carcinoma.